Investigators of the HERACLES A study, a phase II trial of trastuzumab and lapatinib in chemotherapy and EGFR antibody-refractory HER2-positive mCRC patients, reported that ctDNA precisely predicted the response to anti-HER2 therapy in HER2-positive CRC [72]. The gene discussed is ERBB2; the disease is colorectal carcinoma.